mRNA vaccine development for cholangiocarcinoma: a precise pipeline

Tian-Yu Tang; Xing Huang; Gang Zhang; Ming-Hao Lu; Ting-Bo Liang

doi:10.1186/s40779-022-00399-8

mRNA vaccine development for cholangiocarcinoma: a precise pipeline

Mil Med Res. 2022 Jul 12;9(1):40. doi: 10.1186/s40779-022-00399-8.

Authors

Tian-Yu Tang^#^{1

2

3

4

5}, Xing Huang^#^{6

7

8

9

10}, Gang Zhang^{1

2

3

4

5}, Ming-Hao Lu^{1

2

3

4

5}, Ting-Bo Liang^{11

12

13

14

15}

Affiliations

¹ Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
² Zhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China.
³ Zhejiang Clinical Research Center of Hepatobiliary and Pancreatic Diseases, Hangzhou, 310003, China.
⁴ Innovation Center for the Study of Pancreatic Diseases of Zhejiang Province, Hangzhou, 310009, China.
⁵ Cancer Center, Zhejiang University, Hangzhou, 310058, China.
⁶ Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China. huangxing66@zju.edu.cn.
⁷ Zhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China. huangxing66@zju.edu.cn.
⁸ Zhejiang Clinical Research Center of Hepatobiliary and Pancreatic Diseases, Hangzhou, 310003, China. huangxing66@zju.edu.cn.
⁹ Innovation Center for the Study of Pancreatic Diseases of Zhejiang Province, Hangzhou, 310009, China. huangxing66@zju.edu.cn.
¹⁰ Cancer Center, Zhejiang University, Hangzhou, 310058, China. huangxing66@zju.edu.cn.
¹¹ Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China. liangtingbo@zju.edu.cn.
¹² Zhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China. liangtingbo@zju.edu.cn.
¹³ Zhejiang Clinical Research Center of Hepatobiliary and Pancreatic Diseases, Hangzhou, 310003, China. liangtingbo@zju.edu.cn.
¹⁴ Innovation Center for the Study of Pancreatic Diseases of Zhejiang Province, Hangzhou, 310009, China. liangtingbo@zju.edu.cn.
¹⁵ Cancer Center, Zhejiang University, Hangzhou, 310058, China. liangtingbo@zju.edu.cn.

^# Contributed equally.

Abstract

Cholangiocarcinoma (CHOL) is one of the most aggressive tumors worldwide and cannot be effectively treated by conventional and novel treatments, including immune checkpoint blockade therapy. The mRNA vaccine-based immunotherapeutic strategy has attracted much attention for various diseases, however, its application in CHOL is limited due to the thoughtlessness in the integration of vaccine design and patient selection. A recent study established an integrated path for identifying potent CHOL antigens for mRNA vaccine development and a precise stratification for identifying CHOL patients who can benefit from the mRNA vaccines. In spite of a promising prospect, further investigations should identify immunogenic antigens and onco-immunological characteristics of CHOL to guide the clinical application of CHOL mRNA vaccines in the future.

Keywords: Cholangiocarcinoma (CHOL); Immune microenvironment; Immune subtype; Tumor antigen; mRNA vaccine.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Bile Duct Neoplasms*
Bile Ducts, Intrahepatic
Cholangiocarcinoma*
Humans
RNA, Messenger
Vaccines, Synthetic
mRNA Vaccines

Substances

RNA, Messenger
Vaccines, Synthetic
mRNA Vaccines